Overall, these findings suggest that the potential benefits of ATH-1105 against ALS pathogenesis would not be specific to cases primarily driven by TDP-43 mutations but may be etiologically agnostic. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.